Biomotion Sciences Ordinary Shares (SLXN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomotion Sciences Ordinary Shares (SLXN) has a cash flow conversion efficiency ratio of -66.477x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($44.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SLXN market cap overview for the company's overall valuation and market capitalisation.
Biomotion Sciences Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Biomotion Sciences Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biomotion Sciences Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomotion Sciences Ordinary Shares ranked by their cash flow conversion efficiency. Explore Biomotion Sciences Ordinary Shares (SLXN) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sungmoon Electronics Co Ltd
KO:014915
|
0.037x |
|
Niraj Ispat Industries Limited
NSE:NIRAJISPAT
|
0.006x |
|
Totalindo Eka Persada Tbk PT
JK:TOPS
|
-0.009x |
|
Boxlight Corp Class A
NASDAQ:BOXL
|
2.511x |
|
Ace Integrated Solutions Limited
NSE:ACEINTEG
|
0.021x |
|
DigiAsia Corp
NASDAQ:FAAS
|
-0.018x |
|
Induct AS
OL:INDCT
|
N/A |
|
Baillie Gifford China Growth Trust PLC
LSE:BGCG
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Biomotion Sciences Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Biomotion Sciences Ordinary Shares from 2020 to 2025. View today's stock price for Biomotion Sciences Ordinary Shares for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.60 Million | $-10.82 Million | -4.156x | -297.47% |
| 2024-12-31 | $-3.99 Million | $-8.40 Million | 2.105x | +460.29% |
| 2023-12-31 | $-12.06 Million | $-4.53 Million | 0.376x | -20.26% |
| 2022-12-31 | $-7.08 Million | $-3.33 Million | 0.471x | +3946.78% |
| 2021-12-31 | $114.91 Million | $-1.41 Million | -0.012x | -102.78% |
| 2020-12-31 | $-169.99K | $-75.00K | 0.441x | -- |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more